$SLN

Silence Therapeutics plc (Nasdaq: SLN) said it closed an upsized underwritten public offering of 14,907,407 ADSs at $13.50 per ADS, with underwriters fully exercising their option for 1,944,444 additional ADSs. Gross proceeds were about $201.3 million before fees. Jefferies, Morgan Stanley, Cantor and William Blair managed the deal.

Richard Griffiths filed Amendment No. 11 reporting beneficial ownership of 14,391,498 Silence Therapeutics plc ordinary shares, or 7.97% of the class, based on 180,628,068 shares outstanding. Holdings include ADSs via Ora Capital Limited and Cream Capital Limited plus direct shares. The filing cites dilution from share capital increases and open-market ADS sales, including 5,484,320 ADSs sold Aug 10-12, 2026 for $87 proceeds.

Silence Therapeutics plc (SLN) reported Schedule 13G ownership updates. Invus Public Equities, L.P. held 8,707,287 ordinary shares (2,902,429 ADSs), or 6.1% of the class as of June 30, 2026. Avicenna Life Sci Master Fund LP held 1,227,027 shares (409,009 ADSs), or 0.9%. Raymond Debbane may be deemed to own 9,934,314 shares (7.0%) via controlled entities.

Silence Therapeutics plc launched an underwritten U.S. ADS offering of about $150m, priced at $13.50 per ADS for 12,962,963 ADS, targeting gross proceeds of about $175m. AbCellera Biologics commenced a $200m underwritten common share offering. Beyang Therapeutics raised nearly $30m Series A, and Remepy closed a $36m Series A to fund Phase III Hybridopa.

Silence Therapeutics plc (SLN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d168365dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 12,962,963 AMERICAN DEPOSITARY SHARES OF THE COMPANY, EACH REPRESENTING THREE ORDINARY SHARES, NOMINAL VALUE £0.05 PER SHARE SILENCE THERAPEUTICS PLC UNDERWRITING AGREEMENT August 11, 2026 JEFFERIES LLC MORGAN STANLEY & CO. LLC

Silence Therapeutics (SLN) shares fell 1.8% in pre-open after the company priced an underwritten public offering of about 12.96M ADS at $13.50, targeting about $175M gross proceeds, with an option for underwriters to buy up to 1.94M more ADS. The move followed positive Phase 2 SANRECO topline results for divesiran and a Q2 2026 net loss of $0.09 per share.

Silence Therapeutics, a UK biotech, priced a $175 million offering in the US, according to the report. The piece also notes that European equities traded in the US as American Depositary Receipts rose in Tuesday trading. The offering size may affect dilution and near-term liquidity for investors.

Silence Therapeutics priced an upsized underwritten public offering of 12,962,963 ADSs at $13.50 per ADS, each ADS representing three ordinary shares. Gross proceeds are expected at about $175 million, with a 30-day option for underwriters to buy up to 1,944,444 additional ADSs. The offering is expected to close around Aug. 13, 2026.

Silence Therapeutics said it priced an upsized $175 million underwritten public offering, according to the company. The announcement covers the financing terms for the share sale, which may affect the company’s capital structure and near-term funding outlook for investors.

Biotech stocks hit 52-week highs Aug. 10 on trial and earnings updates. Silence Therapeutics (SLN) rose about 29% to $17.58 after Phase 2 SANRECO topline results for divesiran and a reduced Q2 net loss, plus an announced ~$150M ADS offering. AbCellera (ABCL) gained ~34% to $10.01 on Phase 2 ABCL635 data. Cumberland (CPIX) reached $8.45 on Phase 2 Ifetroban progress. Celldex (CLDX) rose to $43.21 on Barzolvolimab Phase 3/2 readouts. Biodesix (BDSX) hit $25.51 after Q2 revenue of $26.9M and FY gui